Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL51390 | 1.00 | LMNA (0.42) | LMNATHRBCA2 | |
| SCHEMBL50813 | 0.96 | LMNA (0.44) | LMNATHRBCA2 | |
| SCHEMBL48144 | 0.96 | LMNA (0.44) | LMNATHRBCA2 | |
| SCHEMBL51644 | 0.96 | LMNA (0.44) | LMNATHRBCA2 | |
| SCHEMBL1829883 | 0.96 | LMNA (0.44) | LMNATHRBCA2 | |
| SCHEMBL534399 | 0.96 | LMNA (0.44) | LMNATHRBCA2 | |
| SCHEMBL248899 | 0.96 | LMNA (0.44) | LMNATHRBCA2 | |
| SCHEMBL8841133 | 0.96 | LMNA (0.44) | LMNATHRBCA2 | |
| SCHEMBL29105556 | 0.96 | LMNA (0.44) | LMNATHRBCA2 | |
| SCHEMBL15050633 | 0.96 | LMNA (0.44) | LMNATHRBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318877-B2 | Ethylene tetrafluoroethylene (meth)acrylate copolymers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2276781-B1 | ETHYLENE-TETRAFLUOROETHYLENE INTERMEDIATES | DU PONT (US) | 2012-11-07 | — | — | EP | disclosed |
| US-8212064-B2 | Ethylene tetrafluoroethylene intermediates | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2283051-B1 | ETHYLENE TETRAFLUOROETHYLENE (METH)ACRYLATE COPOLYMERS | DU PONT (US) | 2012-02-08 | — | — | EP | disclosed |
| US-8049040-B2 | Ethylene-tetrafluoroethylene phosphate composition | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2283051-A1 | ETHYLENE TETRAFLUOROETHYLENE (METH)ACRYLATE COPOLYMERS | E. I. du Pont de Nemours and Company (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143194-A1 | ETHYLENE TETRAFLUOROETHYLENE (METH)ACRYLATE COPOLYMERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090291222-A1 | Ethylene tetrafluoroethylene (meth)acrylate copolymers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090286885-A1 | Ethylene-tetrafluoroethylene phosphate composition | E.I. DU PONT DE NEMUOURS AND COMPANY (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090287010-A1 | Ethylene-tetrafluoroethylene intermediates | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286885-A1 | Ethylene-tetrafluoroethylene phosphate composition | TWF2, CLCN2, KCNN2 | LMNA 2452/4885THRB 2845/4885CA2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.